Compare ELME & HROW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ELME | HROW |
|---|---|---|
| Founded | 1960 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.4B |
| IPO Year | N/A | N/A |
| Metric | ELME | HROW |
|---|---|---|
| Price | $17.37 | $47.21 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 8 |
| Target Price | $15.00 | ★ $68.86 |
| AVG Volume (30 Days) | ★ 1.7M | 535.4K |
| Earning Date | 10-23-2025 | 11-10-2025 |
| Dividend Yield | ★ 4.14% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $246,959,000.00 | ★ $250,042,000.00 |
| Revenue This Year | N/A | $39.05 |
| Revenue Next Year | N/A | $40.48 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 3.10 | ★ 47.83 |
| 52 Week Low | $13.95 | $20.85 |
| 52 Week High | $18.08 | $51.30 |
| Indicator | ELME | HROW |
|---|---|---|
| Relative Strength Index (RSI) | 64.36 | 60.58 |
| Support Level | $16.38 | $44.48 |
| Resistance Level | $17.34 | $47.90 |
| Average True Range (ATR) | 0.12 | 2.46 |
| MACD | 0.01 | 0.82 |
| Stochastic Oscillator | 80.56 | 68.13 |
Elme Communities is a real estate investment trust engaged in owning and operating properties in the greater Washington DC metropolitan area. The company's real estate portfolio is comprised of office, retail, and multifamily properties located near transportation nodes. Washington REIT derives nearly all of its income in the form of rental revenue from tenants organized into long-term leases. The company's office assets contribute the majority of this income, while the rest is split fairly evenly between its retail and multifamily locations. Washington REIT's tenants are banking, consulting, law, and financial services firms.
Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company helps U.S. eyecare professionals preserve the gift of sight by making its comprehensive portfolio of prescription and non-prescription pharmaceutical products accessible and affordable to millions of Americans. Its operating segments are The Branded segment includes activities of the Company's FDA-approved ophthalmology pharmaceutical products, including the out-licensing of rights to certain of branded products; and The ImprimisRx segment represents activities in the Company's ophthalmology-focused pharmaceutical compounding business.